IDEXX LABORATORIES INC /DE Lease Income
IDEXX LABORATORIES INC /DE (IDXX) reported Lease Income of $3.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseIncome · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE lease income for the quarter ending 2026-06-30 was $3.90M, a 5.41% increase year-over-year.
- IDEXX LABORATORIES INC /DE lease income for the quarter ending 2026-03-31 was $3.80M, a 15.15% increase year-over-year.
- IDEXX LABORATORIES INC /DE lease income for the quarter ending 2025-12-31 was $4.00M, a 21.21% increase year-over-year.
- IDEXX LABORATORIES INC /DE lease income for the quarter ending 2025-09-30 was $4.80M, a 37.14% increase year-over-year.
- IDEXX LABORATORIES INC /DE lease income for fiscal 2025 was $15.80M, a 13.67% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE lease income for fiscal 2024 was $13.90M, a 32.85% decline from fiscal 2023.
- IDEXX LABORATORIES INC /DE lease income for fiscal 2023 was $20.70M, a 1.97% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE lease income for fiscal 2022 was $20.30M, a 2.40% decline from fiscal 2021.
| Period end | Lease Income 3 month | Lease Income 6 month | Lease Income 9 month | Lease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.90M 10-Q · filed 2026-08-04 | $7.70M 10-Q · filed 2026-08-04 | $11.70M derived: sum of 3 quarters · filed 2026-08-04 | $16.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $3.80M 10-Q · filed 2026-05-05 | $7.80M derived: sum of 2 quarters · filed 2026-05-05 | $12.60M derived: sum of 3 quarters · filed 2026-05-05 | $16.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.80M derived: sum of 2 quarters · filed 2026-02-20 | $12.50M derived: sum of 3 quarters · filed 2026-08-04 | $15.80M 10-K · filed 2026-02-20 |
| 2025-09-30 | $4.80M 10-Q · filed 2025-11-03 | $8.50M derived: sum of 2 quarters · filed 2026-08-04 | $11.80M 10-Q · filed 2025-11-03 | $15.10M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $3.70M 10-Q · filed 2026-08-04 | $7.00M 10-Q · filed 2026-08-04 | $10.30M derived: sum of 3 quarters · filed 2026-08-04 | $13.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $3.30M 10-Q · filed 2026-05-05 | $6.60M derived: sum of 2 quarters · filed 2026-05-05 | $10.10M derived: sum of 3 quarters · filed 2026-05-05 | $13.40M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $6.80M derived: sum of 2 quarters · filed 2026-02-20 | $10.10M derived: sum of 3 quarters · filed 2026-02-20 | $13.90M 10-K · filed 2026-02-20 |
| 2024-09-30 | $3.50M 10-Q · filed 2025-11-03 | $6.80M derived: sum of 2 quarters · filed 2025-11-03 | $10.60M 10-Q · filed 2025-11-03 | $16.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $3.30M 10-Q · filed 2025-08-04 | $7.20M 10-Q · filed 2025-08-04 | $12.50M derived: sum of 3 quarters · filed 2026-02-20 | $17.80M derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $3.80M 10-Q · filed 2025-05-01 | $9.20M derived: sum of 2 quarters · filed 2026-02-20 | $14.50M derived: sum of 3 quarters · filed 2026-02-20 | $20.00M derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $5.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $10.70M derived: sum of 2 quarters · filed 2026-02-20 | $16.20M derived: sum of 3 quarters · filed 2026-02-20 | $20.70M 10-K · filed 2026-02-20 |
| 2023-09-30 | $5.30M 10-Q · filed 2024-10-31 | $10.80M derived: sum of 2 quarters · filed 2024-10-31 | $15.30M 10-Q · filed 2024-10-31 | $20.10M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $5.50M 10-Q · filed 2024-08-06 | $10.00M 10-Q · filed 2024-08-06 | $14.80M derived: sum of 3 quarters · filed 2025-02-21 | $20.40M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $4.50M 10-Q · filed 2024-05-01 | $9.30M derived: sum of 2 quarters · filed 2025-02-21 | $14.90M derived: sum of 3 quarters · filed 2025-02-21 | $19.80M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $10.40M derived: sum of 2 quarters · filed 2025-02-21 | $15.30M derived: sum of 3 quarters · filed 2025-02-21 | $20.30M 10-K · filed 2025-02-21 |
| 2022-09-30 | $5.60M 10-Q · filed 2023-11-01 | $10.50M derived: sum of 2 quarters · filed 2023-11-01 | $15.50M 10-Q · filed 2023-11-01 | $20.50M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $4.90M 10-Q · filed 2023-08-01 | $9.90M 10-Q · filed 2023-08-01 | $14.90M derived: sum of 3 quarters · filed 2024-02-22 | $21.20M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $5.00M 10-Q · filed 2023-05-02 | $10.00M derived: sum of 2 quarters · filed 2024-02-22 | $16.30M derived: sum of 3 quarters · filed 2024-02-22 | $21.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $11.30M derived: sum of 2 quarters · filed 2024-02-22 | $16.00M derived: sum of 3 quarters · filed 2024-02-22 | $20.80M 10-K · filed 2024-02-22 |
| 2021-09-30 | $6.30M 10-Q · filed 2022-11-01 | $11.00M derived: sum of 2 quarters · filed 2022-11-01 | $15.80M 10-Q · filed 2022-11-01 | $21.10M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $4.70M 10-Q · filed 2022-08-02 | $9.50M 10-Q · filed 2022-08-02 | $14.80M derived: sum of 3 quarters · filed 2022-08-02 | $19.30M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $4.80M 10-Q · filed 2022-05-04 | $10.10M derived: sum of 2 quarters · filed 2022-05-04 | $14.60M derived: sum of 3 quarters · filed 2022-05-04 | $18.10M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $9.80M derived: sum of 2 quarters · filed 2022-02-16 | $13.30M derived: sum of 3 quarters · filed 2022-02-16 | $17.50M 10-K · filed 2022-02-16 |
| 2020-09-30 | $4.50M 10-Q · filed 2021-11-02 | $8.00M derived: sum of 2 quarters · filed 2021-11-02 | $12.20M 10-Q · filed 2021-11-02 | $18.50M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $3.50M 10-Q · filed 2021-07-30 | $7.70M 10-Q · filed 2021-07-30 | $14.00M derived: sum of 3 quarters · filed 2021-07-30 | $19.30M derived: sum of 4 quarters · filed 2021-07-30 |
| 2020-03-31 | $4.20M 10-Q · filed 2021-05-04 | $10.50M derived: sum of 2 quarters · filed 2021-05-04 | $15.80M derived: sum of 3 quarters · filed 2021-05-04 | $20.40M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $11.60M derived: sum of 2 quarters · filed 2021-02-12 | $16.20M derived: sum of 3 quarters · filed 2021-02-12 | $20.80M 10-K · filed 2021-02-12 |
| 2019-09-30 | $5.30M 10-Q · filed 2020-10-29 | $9.90M derived: sum of 2 quarters · filed 2020-10-29 | $14.50M 10-Q · filed 2020-10-29 | $17.70M derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | $4.60M 10-Q · filed 2020-07-31 | $9.20M 10-Q · filed 2020-07-31 | $12.40M derived: sum of 3 quarters · filed 2020-07-31 | $15.40M derived: sum of 4 quarters · filed 2020-07-31 |
| 2019-03-31 | $4.60M 10-Q · filed 2020-04-30 | $7.80M derived: sum of 2 quarters · filed 2020-04-30 | $10.80M derived: sum of 3 quarters · filed 2020-04-30 | $13.90M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-14 | $6.20M derived: sum of 2 quarters · filed 2020-02-14 | $9.30M derived: sum of 3 quarters · filed 2020-02-14 | $12.20M 10-K · filed 2020-02-14 |
| 2018-09-30 | $3.00M 10-Q · filed 2019-10-31 | $6.10M derived: sum of 2 quarters · filed 2019-10-31 | $9.00M 10-Q · filed 2019-10-31 | |
| 2018-06-30 | $3.10M 10-Q · filed 2019-08-01 | $6.00M 10-Q · filed 2019-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |